Lyell Wealth Management LP Has $15.49 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Lyell Wealth Management LP grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 29,768 shares of the medical research company’s stock after purchasing an additional 408 shares during the quarter. Thermo Fisher Scientific comprises approximately 1.4% of Lyell Wealth Management LP’s holdings, making the stock its 18th largest holding. Lyell Wealth Management LP’s holdings in Thermo Fisher Scientific were worth $15,486,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. AMF Tjanstepension AB acquired a new stake in Thermo Fisher Scientific during the 3rd quarter worth $42,409,000. Howard Capital Management Group LLC raised its stake in Thermo Fisher Scientific by 0.5% during the 3rd quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company’s stock worth $33,759,000 after buying an additional 286 shares during the period. Vest Financial LLC raised its stake in Thermo Fisher Scientific by 205.1% during the 3rd quarter. Vest Financial LLC now owns 1,620 shares of the medical research company’s stock worth $1,002,000 after buying an additional 1,089 shares during the period. Ledyard National Bank raised its stake in shares of Thermo Fisher Scientific by 4.4% in the 3rd quarter. Ledyard National Bank now owns 3,165 shares of the medical research company’s stock valued at $1,958,000 after purchasing an additional 132 shares during the period. Finally, Graybill Wealth Management LTD. lifted its holdings in shares of Thermo Fisher Scientific by 1.8% in the third quarter. Graybill Wealth Management LTD. now owns 12,506 shares of the medical research company’s stock valued at $7,736,000 after purchasing an additional 223 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $522.91 on Wednesday. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The business’s 50 day moving average price is $548.15 and its two-hundred day moving average price is $568.62. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The company has a market cap of $200.01 billion, a PE ratio of 31.63, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific announced that its Board of Directors has initiated a stock repurchase plan on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to purchase up to 2% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Royal Bank of Canada cut their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Barclays cut their price target on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Bank of America cut their price target on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Bernstein Bank boosted their price target on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a report on Tuesday, October 22nd. Finally, Morgan Stanley upped their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Four analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $658.00.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the sale, the chief executive officer now directly owns 111,192 shares in the company, valued at approximately $58,960,669.92. The trade was a 8.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the sale, the executive vice president now owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 20,125 shares of company stock valued at $11,231,699. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.